---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343428"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-08-11T11:15:17+00:00"
generated_at: "2026-08-11T11:20:11.804181+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q2 net loss $7.7M, $49M financing, FDA aligns on AP trial

## Summary
- Net loss Q2 2026 $7.7M ($0.45/share) vs $6.0M ($0.40) year ago.
- Cash $18.6M at June 30, 2026; expected to fund operations into H2 2027.
- Private placement up to ~$49M gross (~$15M upfront) to advance pulmonary hypertension program.
- FDA aligned on Phase 2b design for Auxora in acute pancreatitis; primary endpoint new-onset severe respiratory failure.
- Auxora Phase 1b PAH data and CM5480 IND submission both anticipated mid-2027.

## SEC filing metadata
- accession: 0001193125-26-343428
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-08-11T11:15:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/0001193125-26-343428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343428
- JSON: https://secwatch.observer/filing/0001193125-26-343428.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.